O	0	10	Activation	Activation	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	20	signal	signal	NN	B-NP
O	21	31	transducer	transducer	NN	I-NP
O	32	35	and	and	CC	I-NP
O	36	45	activator	activator	NN	I-NP
O	46	48	of	of	IN	B-PP
O	49	62	transcription	transcription	NN	B-NP
O	63	64	3	3	CD	I-NP
O	65	72	through	through	IN	B-PP
O	73	74	a	a	DT	B-NP
O	75	89	phosphomimetic	phosphomimetic	JJ	I-NP
O	90	96	serine	serine	NN	I-NP
O	97	100	727	727	CD	I-NP
O	101	109	promotes	promote	VBZ	B-VP
B-Organ	110	118	prostate	prostate	NN	B-NP
O	119	132	tumorigenesis	tumorigenesis	NN	I-NP
O	133	144	independent	independent	JJ	B-ADJP
O	145	147	of	of	IN	B-PP
O	148	156	tyrosine	tyrosine	NN	B-NP
O	157	160	705	705	CD	I-NP
O	161	176	phosphorylation	phosphorylation	NN	I-NP
O	176	177	.	.	.	O

O	179	189	Aberrantly	Aberrantly	RB	B-NP
O	190	199	activated	activate	VBN	I-NP
O	200	206	signal	signal	NN	I-NP
O	207	217	transducer	transducer	NN	I-NP
O	218	221	and	and	CC	I-NP
O	222	231	activator	activator	NN	I-NP
O	232	234	of	of	IN	B-PP
O	235	248	transcription	transcription	NN	B-NP
O	249	250	3	3	CD	I-NP
O	251	252	(	(	(	O
O	252	257	Stat3	Stat3	NN	B-NP
O	257	258	)	)	)	O
O	259	261	is	be	VBZ	B-VP
O	262	272	implicated	implicate	VBN	I-VP
O	273	275	in	in	IN	B-PP
O	276	279	the	the	DT	B-NP
O	280	291	development	development	NN	I-NP
O	292	294	of	of	IN	B-PP
O	295	302	various	various	JJ	B-NP
O	303	308	human	human	JJ	I-NP
B-Cancer	309	316	cancers	cancer	NNS	I-NP
O	316	317	.	.	.	O

O	318	322	Y705	Y705	NN	B-NP
O	323	338	phosphorylation	phosphorylation	NN	I-NP
O	339	341	is	be	VBZ	B-VP
O	342	356	conventionally	conventionally	RB	I-VP
O	357	364	thought	think	VBN	I-VP
O	365	367	to	to	TO	I-VP
O	368	370	be	be	VB	I-VP
O	371	379	required	require	VBN	I-VP
O	380	383	for	for	IN	B-PP
O	384	389	Stat3	Stat3	NN	B-NP
O	390	396	signal	signal	NN	I-NP
O	396	397	-	-	HYPH	B-NP
O	397	406	dependent	dependent	JJ	I-NP
O	407	417	activation	activation	NN	I-NP
O	418	421	and	and	CC	O
O	422	427	seems	seem	VBZ	B-VP
O	428	430	to	to	TO	I-VP
O	431	435	play	play	VB	I-VP
O	436	438	an	an	DT	B-NP
O	439	448	essential	essential	JJ	I-NP
O	449	453	role	role	NN	I-NP
O	454	456	in	in	IN	B-PP
O	457	461	some	some	DT	B-NP
B-Cancer	462	474	malignancies	malignancy	NNS	I-NP
O	474	475	.	.	.	O

O	476	484	Recently	Recently	RB	B-ADVP
O	484	485	,	,	,	O
O	486	488	it	it	PRP	B-NP
O	489	492	was	be	VBD	B-VP
O	493	498	shown	show	VBN	I-VP
O	499	503	that	that	IN	B-SBAR
O	504	509	Stat3	Stat3	NN	B-NP
O	510	512	is	be	VBZ	B-VP
O	513	522	activated	activate	VBN	I-VP
O	523	530	through	through	IN	B-PP
O	531	536	novel	novel	JJ	B-NP
O	537	540	and	and	CC	I-NP
O	541	553	noncanonical	noncanonical	JJ	I-NP
O	554	564	mechanisms	mechanism	NNS	I-NP
O	564	565	,	,	,	O
O	566	575	including	include	VBG	B-PP
O	576	591	phosphorylation	phosphorylation	NN	B-NP
O	592	594	at	at	IN	B-PP
O	595	599	S727	S727	NN	B-NP
O	599	600	.	.	.	O

O	601	605	Here	Here	RB	B-ADVP
O	605	606	,	,	,	O
O	607	609	we	we	PRP	B-NP
O	610	621	investigate	investigate	VBP	B-VP
O	622	626	S727	S727	NN	B-NP
O	627	642	phosphorylation	phosphorylation	NN	I-NP
O	643	645	of	of	IN	B-PP
O	646	651	Stat3	Stat3	NN	B-NP
O	652	655	and	and	CC	O
O	656	659	its	its	PRP$	B-NP
O	660	670	subsequent	subsequent	JJ	I-NP
O	671	678	effects	effect	NNS	I-NP
O	679	681	in	in	IN	B-PP
B-Cancer	682	690	prostate	prostate	NN	B-NP
I-Cancer	691	697	cancer	cancer	NN	I-NP
O	698	709	development	development	NN	I-NP
O	709	710	,	,	,	O
O	711	722	independent	independent	JJ	B-ADJP
O	723	725	of	of	IN	B-PP
O	726	730	Y705	Y705	NN	B-NP
O	731	746	phosphorylation	phosphorylation	NN	I-NP
O	746	747	,	,	,	O
O	748	753	using	use	VBG	B-VP
O	754	761	mutated	mutate	VBN	B-NP
O	762	767	Stat3	Stat3	NN	I-NP
O	768	770	in	in	IN	B-PP
O	771	774	the	the	DT	B-NP
O	775	780	human	human	JJ	I-NP
B-Cell	781	789	prostate	prostate	NN	I-NP
I-Cell	790	796	cancer	cancer	NN	I-NP
I-Cell	797	801	cell	cell	NN	I-NP
I-Cell	802	806	line	line	NN	I-NP
I-Cell	807	812	LNCaP	LNCaP	NN	I-NP
O	812	813	.	.	.	O

O	814	816	We	We	PRP	B-NP
O	817	821	show	show	VBP	B-VP
O	822	830	mutation	mutation	NN	B-NP
O	831	833	of	of	IN	B-PP
O	834	838	S727	S727	NN	B-NP
O	839	841	to	to	TO	B-PP
O	842	845	the	the	DT	B-NP
O	846	860	phosphomimetic	phosphomimetic	JJ	I-NP
O	861	868	residue	residue	NN	I-NP
O	869	872	Glu	Glu	NN	I-NP
O	872	873	,	,	,	O
O	874	877	and	and	CC	O
O	878	890	inactivation	inactivation	NN	B-NP
O	891	893	of	of	IN	B-PP
O	894	898	Y705	Y705	NN	B-NP
O	899	900	(	(	(	O
O	900	905	Y705F	Y705F	NN	B-NP
O	905	906	/	/	SYM	B-NP
O	906	911	S727E	S727E	NN	I-NP
O	911	912	)	)	)	O
O	913	921	resulted	result	VBD	B-VP
O	922	924	in	in	IN	B-PP
O	925	926	a	a	DT	B-NP
O	927	937	remarkable	remarkable	JJ	I-NP
O	938	944	growth	growth	NN	I-NP
O	945	954	advantage	advantage	NN	I-NP
O	955	957	in	in	IN	B-PP
O	958	961	low	low	JJ	B-NP
O	961	962	-	-	HYPH	I-NP
B-Organism_substance	962	967	serum	serum	NN	I-NP
O	967	968	,	,	,	O
O	969	977	enhanced	enhance	VBD	B-VP
O	978	987	anchorage	anchorage	NN	B-NP
O	987	988	-	-	HYPH	B-NP
O	988	999	independent	independent	JJ	I-NP
O	1000	1006	growth	growth	NN	I-NP
O	1007	1009	in	in	IN	B-PP
O	1010	1014	soft	soft	JJ	B-NP
O	1015	1019	agar	agar	NN	I-NP
O	1019	1020	,	,	,	O
O	1021	1024	and	and	CC	O
O	1025	1034	increased	increase	VBN	B-NP
O	1035	1049	tumorigenicity	tumorigenicity	NN	I-NP
O	1050	1052	in	in	IN	B-PP
O	1053	1061	nonobese	nonobese	JJ	B-NP
O	1062	1070	diabetic	diabetic	JJ	I-NP
O	1070	1071	/	/	SYM	I-NP
O	1071	1077	severe	severe	JJ	I-NP
O	1078	1086	combined	combined	JJ	I-NP
O	1087	1102	immunodeficient	immunodeficient	JJ	I-NP
O	1103	1104	(	(	(	O
O	1104	1107	NOD	NOD	NN	B-NP
O	1107	1108	/	/	SYM	O
O	1108	1112	SCID	SCID	NN	O
O	1112	1113	)	)	)	O
O	1114	1118	mice	mouse	NNS	B-NP
O	1118	1119	,	,	,	O
O	1120	1128	possibly	possibly	RB	B-ADVP
O	1129	1131	by	by	IN	B-PP
O	1132	1138	direct	direct	JJ	B-NP
O	1139	1149	activation	activation	NN	I-NP
O	1150	1152	of	of	IN	B-PP
O	1153	1163	downstream	downstream	JJ	B-NP
O	1164	1169	proto	proto	AFX	I-NP
O	1169	1170	-	-	HYPH	I-NP
O	1170	1179	oncogenes	oncogene	NNS	I-NP
O	1180	1181	c	c	NN	I-NP
O	1181	1182	-	-	HYPH	O
O	1182	1185	myc	myc	NN	B-NP
O	1185	1186	,	,	,	O
O	1187	1190	mcl	mcl	NN	B-NP
O	1190	1191	-	-	HYPH	B-NP
O	1191	1192	1	1	CD	I-NP
O	1192	1193	,	,	,	O
O	1194	1197	and	and	CC	O
O	1198	1206	survivin	survivin	NN	B-NP
O	1206	1207	.	.	.	O

B-Cell	1208	1213	Y705F	Y705F	NN	B-NP
I-Cell	1213	1214	/	/	SYM	I-NP
I-Cell	1214	1219	S727E	S727E	NN	I-NP
I-Cell	1220	1226	mutant	mutant	JJ	I-NP
I-Cell	1227	1232	cells	cell	NNS	I-NP
O	1233	1237	were	be	VBD	B-VP
O	1238	1242	more	more	RBR	B-ADJP
O	1243	1251	invasive	invasive	JJ	I-ADJP
O	1252	1256	than	than	IN	B-PP
B-Cell	1257	1262	Y705F	Y705F	NN	B-NP
I-Cell	1262	1263	/	/	SYM	O
I-Cell	1263	1268	S727A	S727A	NN	B-NP
I-Cell	1269	1270	(	(	(	O
I-Cell	1270	1282	inactivation	inactivation	NN	B-NP
I-Cell	1283	1285	of	of	IN	B-PP
I-Cell	1286	1290	Y705	Y705	NN	B-NP
I-Cell	1291	1294	and	and	CC	O
I-Cell	1295	1299	S727	S727	NN	B-NP
I-Cell	1299	1300	)	)	)	O
I-Cell	1301	1307	mutant	mutant	JJ	B-NP
I-Cell	1308	1313	cells	cell	NNS	I-NP
O	1313	1314	,	,	,	O
O	1315	1318	and	and	CC	O
O	1319	1323	more	more	JJR	B-NP
O	1324	1329	Y705F	Y705F	NN	I-NP
O	1329	1330	/	/	SYM	B-NP
O	1330	1335	S727E	S727E	NN	I-NP
O	1336	1342	mutant	mutant	JJ	I-NP
O	1343	1348	Stat3	Stat3	NN	I-NP
O	1349	1352	was	be	VBD	B-VP
O	1353	1362	localized	localize	VBN	I-VP
O	1363	1365	in	in	IN	B-PP
O	1366	1369	the	the	DT	B-NP
B-Cellular_component	1370	1376	nuclei	nucleus	NNS	I-NP
O	1377	1385	relative	relative	JJ	B-ADJP
O	1386	1388	to	to	TO	B-PP
O	1389	1394	Y705F	Y705F	NN	B-NP
O	1394	1395	/	/	SYM	B-NP
O	1395	1400	S727A	S727A	NN	I-NP
O	1401	1407	mutant	mutant	JJ	I-NP
O	1408	1413	Stat3	Stat3	NN	I-NP
O	1414	1416	at	at	IN	B-PP
O	1417	1420	the	the	DT	B-NP
O	1421	1427	steady	steady	JJ	I-NP
O	1428	1433	state	state	NN	I-NP
O	1433	1434	.	.	.	O

O	1435	1446	Furthermore	Furthermore	RB	B-ADVP
O	1446	1447	,	,	,	O
O	1448	1451	the	the	DT	B-NP
O	1452	1457	Y705F	Y705F	NN	I-NP
O	1457	1458	/	/	SYM	B-VP
O	1458	1463	S727E	S727E	NN	B-NP
O	1464	1467	but	but	CC	B-NP
O	1468	1471	not	not	RB	I-NP
O	1472	1475	the	the	DT	B-NP
O	1476	1481	Y705F	Y705F	NN	I-NP
O	1481	1482	/	/	SYM	B-NP
O	1482	1487	S727A	S727A	NN	I-NP
O	1488	1494	mutant	mutant	NN	I-NP
O	1495	1502	induced	induce	VBD	B-VP
O	1503	1512	anchorage	anchorage	NN	B-NP
O	1512	1513	-	-	HYPH	B-NP
O	1513	1524	independent	independent	JJ	I-NP
O	1525	1531	growth	growth	NN	I-NP
O	1532	1534	of	of	IN	B-PP
B-Cell	1535	1547	noncancerous	noncancerous	JJ	B-NP
I-Cell	1548	1556	prostate	prostate	NN	I-NP
I-Cell	1557	1567	epithelial	epithelial	JJ	I-NP
I-Cell	1568	1573	cells	cell	NNS	I-NP
O	1574	1575	(	(	(	O
B-Cell	1575	1579	RWPE	RWPE	NN	B-NP
I-Cell	1579	1580	-	-	HYPH	B-NP
I-Cell	1580	1581	1	1	CD	I-NP
O	1581	1582	)	)	)	O
O	1582	1583	.	.	.	O

O	1584	1586	We	We	PRP	B-NP
O	1587	1594	further	further	RB	B-ADVP
O	1595	1599	show	show	VBP	B-VP
O	1600	1604	that	that	IN	B-SBAR
O	1605	1610	Stat3	Stat3	NN	B-NP
O	1611	1613	is	be	VBZ	B-VP
O	1614	1628	phosphorylated	phosphorylate	VBN	I-VP
O	1629	1631	at	at	IN	B-PP
O	1632	1636	S727	S727	NN	B-NP
O	1637	1639	in	in	IN	B-PP
O	1640	1642	65	65	CD	B-NP
O	1642	1643	%	%	NN	I-NP
O	1644	1646	of	of	IN	B-PP
B-Tissue	1647	1656	malignant	malignant	JJ	B-NP
I-Tissue	1657	1665	prostate	prostate	NN	I-NP
I-Tissue	1666	1673	tissues	tissue	NNS	I-NP
O	1674	1675	(	(	(	O
O	1675	1676	n	n	NN	B-NP
O	1677	1678	=	=	SYM	B-VP
O	1679	1681	20	20	CD	B-NP
O	1681	1682	)	)	)	O
O	1683	1691	relative	relative	JJ	B-ADVP
O	1692	1694	to	to	TO	B-PP
O	1695	1697	25	25	CD	B-NP
O	1697	1698	%	%	NN	I-NP
O	1699	1701	of	of	IN	B-PP
O	1702	1708	normal	normal	JJ	B-NP
B-Tissue	1709	1717	prostate	prostate	NN	I-NP
I-Tissue	1718	1725	tissues	tissue	NNS	I-NP
O	1726	1727	(	(	(	O
O	1727	1728	n	n	NN	B-NP
O	1729	1730	=	=	SYM	B-VP
O	1731	1732	4	4	CD	B-NP
O	1732	1733	)	)	)	O
O	1733	1734	.	.	.	O

O	1735	1743	Moreover	Moreover	RB	B-ADVP
O	1743	1744	,	,	,	O
O	1745	1750	there	there	EX	B-NP
O	1751	1753	is	be	VBZ	B-VP
O	1754	1755	a	a	DT	B-NP
O	1756	1764	positive	positive	JJ	I-NP
O	1765	1776	correlation	correlation	NN	I-NP
O	1777	1784	between	between	IN	B-PP
O	1785	1796	phosphoS727	phosphoS727	NN	B-NP
O	1796	1797	-	-	HYPH	B-NP
O	1797	1802	Stat3	Stat3	NN	I-NP
O	1803	1813	expression	expression	NN	I-NP
O	1814	1817	and	and	CC	O
O	1818	1825	Gleason	Gleason	NN	B-NP
O	1826	1831	score	score	NN	I-NP
O	1832	1834	in	in	IN	B-PP
O	1835	1840	these	these	DT	B-NP
B-Tissue	1841	1849	prostate	prostate	NN	I-NP
I-Tissue	1850	1856	cancer	cancer	NN	I-NP
I-Tissue	1857	1864	tissues	tissue	NNS	I-NP
O	1865	1866	(	(	(	O
O	1866	1867	P	P	NN	B-NP
O	1868	1869	=	=	SYM	B-VP
O	1870	1871	0	0	CD	B-NP
O	1871	1872	.	.	SYM	I-NP
O	1872	1874	05	05	CD	I-NP
O	1874	1875	)	)	)	O
O	1875	1876	.	.	.	O

O	1877	1880	Our	Our	PRP$	B-NP
O	1881	1885	data	datum	NNS	I-NP
O	1886	1893	suggest	suggest	VBP	B-VP
O	1894	1897	for	for	IN	B-PP
O	1898	1901	the	the	DT	B-NP
O	1902	1907	first	first	JJ	I-NP
O	1908	1912	time	time	NN	I-NP
O	1913	1917	that	that	IN	B-ADVP
O	1918	1922	S727	S727	NN	B-NP
O	1923	1938	phosphorylation	phosphorylation	NN	I-NP
O	1939	1941	is	be	VBZ	B-VP
O	1942	1952	sufficient	sufficient	JJ	B-ADJP
O	1953	1955	to	to	TO	B-VP
O	1956	1964	activate	activate	VB	I-VP
O	1965	1970	Stat3	Stat3	NN	B-NP
O	1970	1971	,	,	,	O
O	1972	1979	thereby	thereby	RB	B-VP
O	1980	1987	driving	drive	VBG	I-VP
B-Organ	1988	1996	prostate	prostate	NN	B-NP
O	1997	2010	tumorigenesis	tumorigenesis	NN	I-NP
O	2011	2022	independent	independent	JJ	B-ADJP
O	2023	2025	of	of	IN	B-PP
O	2026	2030	Y705	Y705	NN	B-NP
O	2031	2046	phosphorylation	phosphorylation	NN	I-NP
O	2046	2047	.	.	.	O

